Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 23;15(23):5554.
doi: 10.3390/cancers15235554.

Immune Predictors of Response after Bacillus Calmette-Guérin Treatment in Non-Muscle-Invasive Bladder Cancer

Marta Rodríguez-Izquierdo  1 , Carmen G Del Cañizo  1 , Carolina Rubio  2   3   4 , Ignacio A Reina  2   3   4 , Mario Hernández Arroyo  1 , Alfredo Rodríguez Antolín  1 , Marta Dueñas Porto  2   3   4 , Félix Guerrero-Ramos  1   4   5
Affiliations
Review

Immune Predictors of Response after Bacillus Calmette-Guérin Treatment in Non-Muscle-Invasive Bladder Cancer

Marta Rodríguez-Izquierdo et al. Cancers (Basel). .

Abstract

Bacillus Calmette-Guérin (BCG) has been the standard of care for the treatment of high-risk, non-muscle-invasive bladder cancer (NMIBC) for decades, but 49.6% of high-risk and very-high-risk patients will experience progression to muscle-invasive disease in five years. Furthermore, cytology and cystoscopy entail a high burden for both patients and health care systems due to the need for very long periods of follow-up. Subsequent adjuvant treatment using intravesical immunotherapy with BCG has been shown to be effective in reducing tumor recurrence and progression, but it is not free of severe adverse effects that ultimately diminish patients' quality of life. Because not all patients benefit from BCG treatment, it is of paramount importance to be able to identify responders and non-responders to BCG as soon as possible in order to offer the best available treatment and prevent unnecessary adverse events. The tumor microenvironment (TME), local immune response, and systemic immune response (both adaptive and innate) seem to play an important role in defining responders, although the way they interact remains unclear. A shift towards a proinflammatory immune response in TME is thought to be related to BCG effectiveness. The aim of this review is to collect the most relevant data available regarding BCG's mechanism of action, its role in modulating innate and adaptive immune responses and the secretion of certain cytokines, and their potential use as immunological markers of response; the aim is also to identify promising lines of investigation.

Keywords: Bacillus Calmette–Guérin; bladder cancer; cytokines; immune response; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Mechanism of action of BCG. BCG: Bacillus Calmette–Guérin. Figure made in https://www.biorender.com/ (accessed on 27 October 2023).
See this image and copyright information in PMC

References

    1. IARC . Cancer Today. Estimated Number of New Cases in 2020, Worldwide, Both Sexes, All Ages. IARC; Lyon, France: 2021.
    1. Saginala K., Barsouk A., Aluru J.S., Rawla P., Padala S.A., Barsouk A. Epidemiology of bladder cancer. Med. Sci. 2020;8:15. doi: 10.3390/medsci8010015. - DOI - PMC - PubMed
    1. Ferro M., Barone B., Crocetto F., Lucarelli G., Busetto G.M., del Giudice F., Maggi M., Crocerossa F., Cantiello F., Damiano R., et al. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol. Oncol. 2022;40:e13–e490. doi: 10.1016/j.urolonc.2022.05.016. - DOI - PubMed
    1. Kamat A.M., Li R., O’Donnell M.A., Black P.C., Roupret M., Catto J.W., Comperat E., Ingersoll M.A., Witjes W.P., McConkey D.J., et al. Predicting response to intravesical bacillus Calmette-Guérin immunotherapy: Are we there yet? A systematic review. Eur. Urol. 2017;73:738–748. doi: 10.1016/j.eururo.2017.10.003. - DOI - PubMed
    1. Gontero E.P., Compérat J.L., Dominguez Escrig F., Liedberg P., Mariappan A., Masson-Lecomte A.H., Mostafid B.W.G., van Rhijn M., Rouprêt T., Seisen S.F., et al. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) Eur. Assoc. Urol. 2023;71:447–461.

LinkOut - more resources